×
About 18,555 results

ALLMedicine™ Cholangiocarcinoma Center

Research & Reviews  9,121 results

Liver Inflammation and Hepatobiliary Cancers.
https://doi.org/10.1016/j.trecan.2021.01.012
Trends in Cancer; Leone V, Ali A et. al.

Mar 6th, 2021 - Immune regulation has an important role in cancer development, particularly in organs with continuous exposure to environmental pathogens, such as the liver and gastrointestinal tract. Chronic liver inflammation can lead to the development of hepa...

A possible case of recipient anti-neutrophil and anti-human leukocyte antigen antibody-...
https://doi.org/10.1111/trf.16330
Transfusion Jug R, Anani W et. al.

Mar 5th, 2021 - Transfusion-related acute lung injury (TRALI) is a transfusion complication often mediated by recipient exposure to plasma from donors with human leukocyte antigen (HLA) and human neutrophil antigen (HNA) antibodies. Recipient anti-donor HLA or HN...

Intrahepatic cholangiocarcinoma in a non-cirrhotic liver in a patient with homozygous Z...
https://doi.org/10.1136/bcr-2020-240077
BMJ Case Reports; Vuurberg NE, Van den Boom AL et. al.

Mar 4th, 2021 - Alpha-1 antitrypsin (AAT) deficiency, which is an under-recognised metabolic genetic disorder, is known to cause severe lung disease and liver cirrhosis in about 10%-15% of cases. Patients with AAT deficiency are at a higher risk for developing he...

Hepatectomy is associated with survival in intrahepatic cholangiocarcinoma: An observat...
https://doi.org/10.1097/MD.0000000000024147
Medicine Chen W, Wu Z et. al.

Mar 3rd, 2021 - Liver resection (LR) is a major treatment modality in select patients with stage I-III Intrahepatic cholangiocarcinoma (ICC), yet many studies demonstrated low rates of resection. The aim of the present study is to evaluate whether increasing rese...

Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangi...
https://doi.org/10.1159/000512967
Oncology Pietge H, Sánchez-Velázquez P et. al.

Mar 3rd, 2021 - Unresectable cholangiocarcinoma has a poor prognosis and treatment options are limited. Combined systemic and intrahepatic chemotherapy may improve local control and enable downsizing. The aim of this study was to determine the maximum tolerated d...

see more →

Guidelines  15 results

AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With...
https://doi.org/10.1016/j.cgh.2019.07.011
Clinical Gastroenterology and Hepatology : the Official C... Bowlus CL, Lim JK et. al.

Jul 15th, 2019 - The purpose of this clinical practice update is to define key principles in the surveillance of hepatobiliary cancers including cholangiocarcinoma, gallbladder adenocarcinoma, and hepatocellular carcinoma in patients with primary sclerosing cholan...

Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline
http://ascopubs.org/doi/full/10.1200/JCO.18.02178

Mar 10th, 2019 - PURPOSE To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. METHODS ASCO convened an Expert Panel to conduct a systematic review of the literature on adju...

Clinical practice guidelines for IgG4-related sclerosing cholangitis.
https://doi.org/10.1002/jhbp.596
Journal of Hepato-biliary-pancreatic Sciences; Kamisawa T, Nakazawa T et. al.

Dec 23rd, 2018 - IgG4-related sclerosing cholangitis (IgG4-SC) is a distinct type of cholangitis frequently associated with autoimmune pancreatitis and currently recognized as a biliary manifestation of IgG4-related disease. Although clinical diagnostic criteria o...

Hilar cholangiocarcinoma: expert consensus statement.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527854
HPB : the Official Journal of the International Hepato Pa... Mansour JC, Aloia TA et. al.

Jul 14th, 2015 - An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus meeting of expert panellists met on 15 January 2014 to review current evidence on the management of hilar cholangiocarcinoma in order to establish practice guidelines and...

Asia-Pacific consensus recommendations for endoscopic and interventional management of ...
https://doi.org/10.1111/jgh.12128
Journal of Gastroenterology and Hepatology; Rerknimitr R, Angsuwatcharakon P et. al.

Jan 28th, 2013 - Hilar cholangiocarcinoma (HCCA) is one of the most common types of hepatobiliary cancers reported in the world including Asia-Pacific region. Early HCCA may be completely asymptomatic. When significant hilar obstruction develops, the patient prese...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  9,291 results

Liver Inflammation and Hepatobiliary Cancers.
https://doi.org/10.1016/j.trecan.2021.01.012
Trends in Cancer; Leone V, Ali A et. al.

Mar 6th, 2021 - Immune regulation has an important role in cancer development, particularly in organs with continuous exposure to environmental pathogens, such as the liver and gastrointestinal tract. Chronic liver inflammation can lead to the development of hepa...

A possible case of recipient anti-neutrophil and anti-human leukocyte antigen antibody-...
https://doi.org/10.1111/trf.16330
Transfusion Jug R, Anani W et. al.

Mar 5th, 2021 - Transfusion-related acute lung injury (TRALI) is a transfusion complication often mediated by recipient exposure to plasma from donors with human leukocyte antigen (HLA) and human neutrophil antigen (HNA) antibodies. Recipient anti-donor HLA or HN...

Intrahepatic cholangiocarcinoma in a non-cirrhotic liver in a patient with homozygous Z...
https://doi.org/10.1136/bcr-2020-240077
BMJ Case Reports; Vuurberg NE, Van den Boom AL et. al.

Mar 4th, 2021 - Alpha-1 antitrypsin (AAT) deficiency, which is an under-recognised metabolic genetic disorder, is known to cause severe lung disease and liver cirrhosis in about 10%-15% of cases. Patients with AAT deficiency are at a higher risk for developing he...

Hepatectomy is associated with survival in intrahepatic cholangiocarcinoma: An observat...
https://doi.org/10.1097/MD.0000000000024147
Medicine Chen W, Wu Z et. al.

Mar 3rd, 2021 - Liver resection (LR) is a major treatment modality in select patients with stage I-III Intrahepatic cholangiocarcinoma (ICC), yet many studies demonstrated low rates of resection. The aim of the present study is to evaluate whether increasing rese...

Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangi...
https://doi.org/10.1159/000512967
Oncology Pietge H, Sánchez-Velázquez P et. al.

Mar 3rd, 2021 - Unresectable cholangiocarcinoma has a poor prognosis and treatment options are limited. Combined systemic and intrahepatic chemotherapy may improve local control and enable downsizing. The aim of this study was to determine the maximum tolerated d...

see more →

News  103 results

FDA Approves First Targeted Drug for Bile Duct Cancer
https://www.staging.medscape.com/viewarticle/928959

Apr 19th, 2020 - The US Food and Drug Administration (FDA) has granted accelerated approval of a new targeted therapy for use in some patients with cholangiocarcinoma, a rare cancer of the bile ducts. The product is pemigatinib (Pemazyre, Incyte), an oral kinase i...

FDA Approves First Targeted Drug for Bile Duct Cancer
https://www.medscape.com/viewarticle/928959

Apr 19th, 2020 - The US Food and Drug Administration (FDA) has granted accelerated approval of a new targeted therapy for use in some patients with cholangiocarcinoma, a rare cancer of the bile ducts. The product is pemigatinib (Pemazyre, Incyte), an oral kinase i...

Fast Five Quiz: Cholangiocarcinoma Presentation and Diagnosis
https://reference.medscape.com/viewarticle/922403_1

Feb 19th, 2020 - Cancer of the bile duct, or cholangiocarcinoma, is a malignant neoplasm of the intrahepatic or extrahepatic biliary epithelium. It is the most common biliary tract cancer and the second most common primary hepatic cancer. Although its etiology is ...

Fast Five Quiz: Cholangiocarcinoma Presentation and Diagnosis
https://reference.medscape.com/viewarticle/922403_2

Feb 19th, 2020 - Figure 1. Common bile duct and pancreatic duct Perihilar tumors, also called Klatskin tumors, are the most common cholangiocarcinomas. They occur in the hilum region at the bifurcation of the right and left hepatic ducts. Intrahepatic tumors are t...

Fast Five Quiz: Management of Cholangiocarcinoma
https://reference.medscape.com/viewarticle/922398_3

Feb 19th, 2020 - Even though the rates of resection with tumor-free margins have improved with more aggressive surgical approaches and improved radiologic techniques, recurrence rates remain high (49%-64%). These recurrences usually occur within 2-3 years post-res...

see more →

Patient Education  23 results see all →